Shandong Xinhua Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Shandong Xinhua Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Shandong Xinhua Pharmaceutical Co Ltd (000756) has a cash flow conversion efficiency ratio of 0.012x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.11 Million ≈ $8.21 Million USD) by net assets (CN¥4.70 Billion ≈ $687.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)
Cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. This chart illustrates how Shandong Xinhua Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Shandong Xinhua Pharmaceutical Co Ltd for real-time trading data and today's change.
Shandong Xinhua Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Shandong Xinhua Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shandong Xinhua Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Xinhua Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Shandong Xinhua Pharmaceutical Co Ltd (000756) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intelbras S.A. - Indústria de Telecomunicação Eletrônica Brasileira
SA:INTB3
|
0.150x |
|
Jiangyin Hengrun Heavy
SHG:603985
|
0.009x |
|
First Financial Corporation Indiana
NASDAQ:THFF
|
0.027x |
|
Helia Group Ltd
AU:HLI
|
-0.038x |
|
Shenzhen Asiantime International Construction Co Ltd
SHE:002811
|
0.071x |
|
Hexatronic Group AB
ST:HTRO
|
0.008x |
|
Sudarshan Chemical Industries Limited
NSE:SUDARSCHEM
|
-0.036x |
|
Guilin Seamild Foods Co Ltd
SHE:002956
|
0.081x |
Annual Cash Flow Conversion Efficiency for Shandong Xinhua Pharmaceutical Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Co Ltd from 2015 to 2024. Review Shandong Xinhua Pharmaceutical Co Ltd (000756) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.22 Billion ≈ $763.48 Million |
CN¥367.61 Million ≈ $53.79 Million |
0.070x | +26.84% |
| 2023-12-31 | CN¥4.78 Billion ≈ $698.84 Million |
CN¥265.28 Million ≈ $38.82 Million |
0.056x | -68.13% |
| 2022-12-31 | CN¥4.35 Billion ≈ $636.53 Million |
CN¥758.24 Million ≈ $110.95 Million |
0.174x | +145.62% |
| 2021-12-31 | CN¥3.65 Billion ≈ $534.28 Million |
CN¥259.12 Million ≈ $37.92 Million |
0.071x | -42.72% |
| 2020-12-31 | CN¥3.39 Billion ≈ $496.25 Million |
CN¥420.19 Million ≈ $61.49 Million |
0.124x | +10.66% |
| 2019-12-31 | CN¥3.11 Billion ≈ $455.17 Million |
CN¥348.27 Million ≈ $50.96 Million |
0.112x | -3.33% |
| 2018-12-31 | CN¥2.80 Billion ≈ $409.22 Million |
CN¥323.91 Million ≈ $47.40 Million |
0.116x | -23.39% |
| 2017-12-31 | CN¥2.58 Billion ≈ $377.46 Million |
CN¥389.97 Million ≈ $57.07 Million |
0.151x | -28.45% |
| 2016-12-31 | CN¥2.08 Billion ≈ $304.27 Million |
CN¥439.35 Million ≈ $64.29 Million |
0.211x | +20.25% |
| 2015-12-31 | CN¥1.98 Billion ≈ $290.33 Million |
CN¥348.64 Million ≈ $51.02 Million |
0.176x | -- |
About Shandong Xinhua Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for act… Read more